Lineage Cell Therapeutics Reports Q3 2025 Financial Results with $3.68M Revenue

Lineage Cell Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing total revenues of $3.68 million, a slight decrease of 3% from $3.78 million in the same period last year. The decline was primarily attributed to a $0.3 million drop in royalty and other service revenues, which was partially offset by a $0.2 million increase in collaboration revenues, driven by a new research collaboration agreement with William Demant Invest 2 Aps. For the nine months ending September 30, 2025, total revenues increased by 20% to $7.95 million, compared to $6.63 million in the prior year, largely due to the same collaboration agreement.

Operating expenses for the third quarter decreased by 2% to $7.47 million, down from $7.62 million in the previous year. The reduction was mainly due to a significant decrease in the cost of royalties, which fell by 87% to $5, while research and development expenses rose slightly by 3% to $3.27 million. Notably, the company recorded a substantial impairment charge of $14.84 million related to the abandonment of its VAC platform, contributing to a total operating loss of $3.79 million for the quarter, compared to a loss of $3.84 million in the same quarter of 2024.

Lineage's balance sheet as of September 30, 2025, showed total assets of $89.64 million, a decrease from $113.22 million at the end of 2024. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $40.46 million from $45.79 million. The company's accumulated deficit increased to $467.85 million, reflecting ongoing operational losses. The total liabilities also rose significantly to $68.84 million, largely due to an increase in warrant liabilities, which surged to $45.17 million from $6.16 million at the end of 2024.

Strategically, Lineage continues to advance its lead product candidate, OpRegen, which is in Phase 2a development for treating geographic atrophy secondary to age-related macular degeneration. The company has received a total of $50 million in upfront payments from its collaboration with Roche and is eligible for up to $620 million in additional milestone payments. Furthermore, Lineage has initiated a new clinical study for its OPC1 program, aimed at spinal cord injuries, and has entered into a research collaboration for its ReSonance program targeting hearing loss.

Looking ahead, Lineage anticipates that its current cash reserves, along with potential future revenues from collaborations and ongoing financing efforts, will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the need for additional capital to support its clinical development programs and operational expenses, which may involve equity offerings or other financing strategies. The ongoing geopolitical situation in Israel, where the company conducts its manufacturing operations, remains a potential risk factor that could impact future performance.